Skip to content

Treatment of Psoriasis with Unani Medicine

Assessment of Leptin Gene expression in the pathogenesis of Psoriasis in relation to Unani Philosophy

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/107896
Enrollment
30
Registered
2026-04-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L409- Psoriasis, unspecified

Interventions

Intervention1: Mujun Mundi (oral) and Qairooti Karnab (Ointment): Majun Mundi is given 5 gm BD for 84 days. Qairooti Karnab ointment is applied topically on the affected psoriatic lesions. Interventio

Sponsors

Central Council for research in Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with Psoriasis who are willing to participate in the study.

Exclusion criteria

Exclusion criteria: The Subjects who are unwilling to give the blood sample. Pregnant women, lactating women, cancer patients and mentally disorder people

Design outcomes

Primary

MeasureTime frame
â?¢This study will be providing the expression levels of leptin gene association in psoriasis patients with clinical phenotyping along with the proinflammatory cytokines. This study will reveal the gene expression levels after the drug treatment. Thus, this study may provide possible association of expression level in psoriasis related to clinical phenotyping and clinical pattern of the disease.Timepoint: baseline, 4th month

Secondary

MeasureTime frame
â?¢ Determination of dominant Temperament by special CRF based on Unani Philosophy of Medicine.Timepoint: baseline , 4th month

Countries

India

Contacts

Public ContactTasleem Ahmed

NRIUMSD, Hyderabad

tasleem786@rediffmail.com9304109801

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026